NASDAQ:HTGM

HTG Molecular Diagnostics Competitors

$4.96
-0.13 (-2.55 %)
(As of 04/9/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.87
Now: $4.96
$5.06
50-Day Range
$5.09
MA: $5.95
$7.32
52-Week Range
$3.78
Now: $4.96
$13.80
Volume59,501 shs
Average Volume168,236 shs
Market Capitalization$30.82 million
P/E RatioN/A
Dividend YieldN/A
Beta1.63

Competitors

HTG Molecular Diagnostics (NASDAQ:HTGM) Vs. ILMN, A, MTD, TXG, WAT, and AVTR

Should you be buying HTGM stock or one of its competitors? Companies in the industry of "analytical instruments" are considered alternatives and competitors to HTG Molecular Diagnostics, including Illumina (ILMN), Agilent Technologies (A), Mettler-Toledo International (MTD), 10x Genomics (TXG), Waters (WAT), and Avantor (AVTR).

HTG Molecular Diagnostics (NASDAQ:HTGM) and Illumina (NASDAQ:ILMN) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for HTG Molecular Diagnostics and Illumina, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
Illumina48602.11

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. Illumina has a consensus target price of $370.5789, suggesting a potential downside of 8.13%. Given Illumina's higher possible upside, analysts plainly believe Illumina is more favorable than HTG Molecular Diagnostics.

Insider and Institutional Ownership

90.0% of Illumina shares are owned by institutional investors. 4.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 0.4% of Illumina shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares HTG Molecular Diagnostics and Illumina's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
Illumina19.70%15.93%10.09%

Volatility & Risk

HTG Molecular Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Illumina has a beta of 1.14, suggesting that its share price is 14% more volatile than the S&P 500.

Earnings & Valuation

This table compares HTG Molecular Diagnostics and Illumina's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
Illumina$3.54 billion16.61$1.00 billion$6.5761.40

Illumina has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Illumina, indicating that it is currently the more affordable of the two stocks.

Summary

Illumina beats HTG Molecular Diagnostics on 11 of the 14 factors compared between the two stocks.

HTG Molecular Diagnostics (NASDAQ:HTGM) and Agilent Technologies (NYSE:A) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for HTG Molecular Diagnostics and Agilent Technologies, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
Agilent Technologies081902.70

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. Agilent Technologies has a consensus target price of $104.70, suggesting a potential downside of 20.63%. Given Agilent Technologies' higher possible upside, analysts plainly believe Agilent Technologies is more favorable than HTG Molecular Diagnostics.

Profitability

This table compares HTG Molecular Diagnostics and Agilent Technologies' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
Agilent Technologies13.47%21.02%10.73%

Risk and Volatility

HTG Molecular Diagnostics has a beta of 1.63, indicating that its share price is 63% more volatile than the S&P 500. Comparatively, Agilent Technologies has a beta of 1.04, indicating that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares HTG Molecular Diagnostics and Agilent Technologies' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
Agilent Technologies$5.34 billion7.53$719 million$3.2840.22

Agilent Technologies has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Agilent Technologies, indicating that it is currently the more affordable of the two stocks.

Summary

Agilent Technologies beats HTG Molecular Diagnostics on 10 of the 12 factors compared between the two stocks.

HTG Molecular Diagnostics (NASDAQ:HTGM) and Mettler-Toledo International (NYSE:MTD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for HTG Molecular Diagnostics and Mettler-Toledo International, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
Mettler-Toledo International35101.78

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. Mettler-Toledo International has a consensus target price of $971.3750, suggesting a potential downside of 20.54%. Given Mettler-Toledo International's higher possible upside, analysts plainly believe Mettler-Toledo International is more favorable than HTG Molecular Diagnostics.

Insider and Institutional Ownership

93.2% of Mettler-Toledo International shares are owned by institutional investors. 4.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 3.2% of Mettler-Toledo International shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares HTG Molecular Diagnostics and Mettler-Toledo International's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
Mettler-Toledo International19.36%144.89%21.11%

Volatility & Risk

HTG Molecular Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, Mettler-Toledo International has a beta of 1.04, suggesting that its share price is 4% more volatile than the S&P 500.

Earnings & Valuation

This table compares HTG Molecular Diagnostics and Mettler-Toledo International's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
Mettler-Toledo International$3.01 billion9.48$561.11 million$22.7753.69

Mettler-Toledo International has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Mettler-Toledo International, indicating that it is currently the more affordable of the two stocks.

Summary

Mettler-Toledo International beats HTG Molecular Diagnostics on 10 of the 14 factors compared between the two stocks.

HTG Molecular Diagnostics (NASDAQ:HTGM) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, dividends, valuation and earnings.

Analyst Recommendations

This is a summary of recent ratings for HTG Molecular Diagnostics and 10x Genomics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
10x Genomics01702.88

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. 10x Genomics has a consensus target price of $181.4444, suggesting a potential downside of 6.78%. Given 10x Genomics' higher possible upside, analysts plainly believe 10x Genomics is more favorable than HTG Molecular Diagnostics.

Volatility & Risk

HTG Molecular Diagnostics has a beta of 1.63, suggesting that its share price is 63% more volatile than the S&P 500. Comparatively, 10x Genomics has a beta of 1.39, suggesting that its share price is 39% more volatile than the S&P 500.

Insider and Institutional Ownership

68.8% of 10x Genomics shares are owned by institutional investors. 4.6% of HTG Molecular Diagnostics shares are owned by company insiders. Comparatively, 13.3% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares HTG Molecular Diagnostics and 10x Genomics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
10x Genomics-51.27%-19.98%-14.38%

Earnings & Valuation

This table compares HTG Molecular Diagnostics and 10x Genomics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
10x Genomics$245.89 million86.09$-31,250,000.00($0.80)-243.30

HTG Molecular Diagnostics has higher earnings, but lower revenue than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than HTG Molecular Diagnostics, indicating that it is currently the more affordable of the two stocks.

Summary

10x Genomics beats HTG Molecular Diagnostics on 10 of the 14 factors compared between the two stocks.

HTG Molecular Diagnostics (NASDAQ:HTGM) and Waters (NYSE:WAT) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for HTG Molecular Diagnostics and Waters, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
Waters48101.77

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. Waters has a consensus target price of $224.20, suggesting a potential downside of 27.00%. Given Waters' higher possible upside, analysts plainly believe Waters is more favorable than HTG Molecular Diagnostics.

Risk and Volatility

HTG Molecular Diagnostics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Waters has a beta of 0.97, suggesting that its stock price is 3% less volatile than the S&P 500.

Insider & Institutional Ownership

91.8% of Waters shares are held by institutional investors. 4.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 1.5% of Waters shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares HTG Molecular Diagnostics and Waters' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
Waters22.61%-349.31%21.11%

Earnings and Valuation

This table compares HTG Molecular Diagnostics and Waters' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
Waters$2.41 billion7.92$592.20 million$8.9934.16

Waters has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Waters, indicating that it is currently the more affordable of the two stocks.

Summary

Waters beats HTG Molecular Diagnostics on 9 of the 14 factors compared between the two stocks.

HTG Molecular Diagnostics (NASDAQ:HTGM) and Avantor (NYSE:AVTR) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, dividends, risk, institutional ownership, profitability, analyst recommendations and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for HTG Molecular Diagnostics and Avantor, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
HTG Molecular Diagnostics00303.00
Avantor021402.88

HTG Molecular Diagnostics presently has a consensus target price of $1.1667, suggesting a potential downside of 76.48%. Avantor has a consensus target price of $29.7941, suggesting a potential downside of 6.10%. Given Avantor's higher possible upside, analysts plainly believe Avantor is more favorable than HTG Molecular Diagnostics.

Risk and Volatility

HTG Molecular Diagnostics has a beta of 1.63, suggesting that its stock price is 63% more volatile than the S&P 500. Comparatively, Avantor has a beta of 1.84, suggesting that its stock price is 84% more volatile than the S&P 500.

Insider & Institutional Ownership

84.8% of Avantor shares are held by institutional investors. 4.6% of HTG Molecular Diagnostics shares are held by company insiders. Comparatively, 1.9% of Avantor shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares HTG Molecular Diagnostics and Avantor's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
HTG Molecular Diagnostics-194.78%-101.81%-50.43%
Avantor2.21%44.58%6.85%

Earnings and Valuation

This table compares HTG Molecular Diagnostics and Avantor's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
HTG Molecular Diagnostics$19.20 million1.61$-19,300,000.00($7.65)-0.65
Avantor$6.04 billion3.02$37.80 million$0.5854.71

Avantor has higher revenue and earnings than HTG Molecular Diagnostics. HTG Molecular Diagnostics is trading at a lower price-to-earnings ratio than Avantor, indicating that it is currently the more affordable of the two stocks.

Summary

Avantor beats HTG Molecular Diagnostics on 12 of the 14 factors compared between the two stocks.


HTG Molecular Diagnostics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Illumina logo
ILMN
Illumina
1.6$403.37-0.1%$58.85 billion$3.54 billion93.59Analyst Report
Insider Selling
Agilent Technologies logo
A
Agilent Technologies
1.8$131.91-0.9%$40.19 billion$5.34 billion57.35
Mettler-Toledo International logo
MTD
Mettler-Toledo International
1.3$1,222.41-1.3%$28.51 billion$3.01 billion51.43
10x Genomics logo
TXG
10x Genomics
1.6$194.64-2.3%$21.17 billion$245.89 million-144.18Insider Selling
News Coverage
Gap Up
Waters logo
WAT
Waters
1.3$307.14-1.0%$19.06 billion$2.41 billion38.25
Avantor logo
AVTR
Avantor
1.8$31.73-0.7%$18.24 billion$6.04 billion264.42
Bio-Rad Laboratories logo
BIO
Bio-Rad Laboratories
1.5$602.57-1.7%$17.98 billion$2.31 billion5.16News Coverage
BIO.B
Bio-Rad Laboratories
0.7$579.38-0.0%$17.28 billion$2.31 billion4.96
PerkinElmer logo
PKI
PerkinElmer
1.9$133.39-1.4%$14.95 billion$2.88 billion36.25
Bruker logo
BRKR
Bruker
1.9$68.61-1.7%$10.40 billion$2.07 billion67.27Gap Up
Coherent logo
COHR
Coherent
1.5$265.56-0.6%$6.50 billion$1.23 billion-15.45
Pacific Biosciences of California logo
PACB
Pacific Biosciences of California
1.6$32.16-4.1%$6.21 billion$90.89 million-114.85Gap Down
Berkeley Lights logo
BLI
Berkeley Lights
1.4$47.24-3.9%$3.13 billionN/A0.00Gap Down
Quanterix logo
QTRX
Quanterix
1.2$66.12-0.5%$2.40 billion$56.73 million-58.51Insider Selling
News Coverage
Bionano Genomics logo
BNGO
Bionano Genomics
0.9$7.29-3.3%$2.03 billion$10.13 million-3.84Analyst Upgrade
Analyst Revision
News Coverage
Accelerate Diagnostics logo
AXDX
Accelerate Diagnostics
1.8$8.87-2.1%$543.08 million$9.30 million-6.08News Coverage
Gap Down
Fluidigm logo
FLDM
Fluidigm
1.8$4.60-2.4%$342.92 million$117.24 million-6.87
EyePoint Pharmaceuticals logo
EYPT
EyePoint Pharmaceuticals
1.4$10.01-1.2%$287.70 million$20.36 million-2.94
Harvard Bioscience logo
HBIO
Harvard Bioscience
1.8$6.53-0.3%$260.06 million$116.18 million-36.28Analyst Upgrade
Precipio logo
PRPO
Precipio
1.3$2.05-3.4%$37.17 million$3.13 million0.00
Astrotech logo
ASTC
Astrotech
0.5$1.47-5.4%$36.16 million$490,000.00-1.20High Trading Volume
News Coverage
Gap Down
This page was last updated on 4/11/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.